PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

导出 OA

翻译打印收藏纠错

第一作者： Helen Y,Zou

第一单位： Pfizer World Wide Research and Development, 10724 Science Center Drive, San Diego, CA 92121, USA.

作者： Helen Y,Zou ^[1] ; Luc,Friboulet ^[2] ; David P,Kodack ^[3] ; Lars D,Engstrom ^[1] ; Qiuhua,Li ^[1] ; Melissa,West ^[1] ; Ruth W,Tang ^[1] ; Hui,Wang ^[1] ; Konstantinos,Tsaparikos ^[1] ; Jinwei,Wang ^[1] ; Sergei,Timofeevski ^[1] ; Ryohei,Katayama ^[4] ; Dac M,Dinh ^[1] ; Hieu,Lam ^[1] ; Justine L,Lam ^[1] ; Shinji,Yamazaki ^[1] ; Wenyue,Hu ^[1] ; Bhushankumar,Patel ^[3] ; Divya,Bezwada ^[3] ; Rosa L,Frias ^[2] ; Eugene,Lifshits ^[2] ; Sidra,Mahmood ^[2] ; Justin F,Gainor ^[2] ; Timothy,Affolter ^[1] ; Patrick B,Lappin ^[1] ; Hovhannes,Gukasyan ^[1] ; Nathan,Lee ^[1] ; Shibing,Deng ^[1] ; Rakesh K,Jain ^[3] ; Ted W,Johnson ^[1] ; Alice T,Shaw ^[2] ; Valeria R,Fantin ^[1] ; Tod,Smeal ^[5]

作者单位： Pfizer World Wide Research and Development, 10724 Science Center Drive, San Diego, CA 92121, USA. ^[1] Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA. ^[2] Department of Radiation Oncology, Edwin L. Steele Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. ^[3] Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan. ^[4] Pfizer World Wide Research and Development, 10724 Science Center Drive, San Diego, CA 92121, USA. Electronic address: tod.smeal@pfizer.com. ^[5]